


L1 STRUCTURE UPLOADED

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



L2 0 S L1 SSS SAM

L3 9 S L1 SSS FULL

E OLANZAPINE/CN

SET EXPAND CONTINUOUS

L4 1 S E3

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN

RN 132539-06-1 REGISTRY

ED Entered STN: 08 Mar 1991

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-

(CA INDEX NAME)

OTHER NAMES:

CN Integrol

CN Lanzac

CN LY 170053

CN Olanzapine

CN Oleanz

CN Olenz

CN Olimelt

CN Oliza

CN Oltal

CN Zyprexa

DR 1034315-19-9

MF C17 H20 N4 S

CI COM

SR US Adopted Names Council (USAN)

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,

CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,

DDFU,

DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH,


IPA,

MEDLINE, MRCK*, PATDPASPC, PIRA, PROMT, PROUSDDR, PS, RTECS*,

SYNTHLINE,

TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)



FILE 'HCAPLUS' ENTERED AT 16:42:24 ON 25 MAR 2010
L5 2 S L3 AND L4

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2010 ACS on STN

TI New psychiatric drug formulation with an antipsychotic or antidepressant

and an histamine H3 receptor antagonist for the prevention of psychotropic adverse effects

AB The invention relates to a drug formulation with an antipsychotic or an antidepressant, which causes adverse effects like body weight gain or sedation when administered, and an histamine H3 receptor antagonist or inverse agonist. The histamine H3 receptor antagonist or inverse agonist should be present in the formulation in therapeutically effective quantities to ensure at least one of the three following effects on the adverse effects induced by the antipsychotic or the antidepressant: suppression or limitation of weight gain, suppression or limitation of the decrease in vigilance, enhancement of the pro-cognitive effect of the treatment.

ACCESSION NUMBER: 2005:589 HCAPLUS Full-text

DOCUMENT NUMBER: 142:79960

TITLE: New psychiatric drug formulation with an antipsychotic

or antidepressant and an histamine H3 receptor antagonist for the prevention of psychotropic

adverse

effects

INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte, Jeanne Marie

PATENT ASSIGNEE(S): Bioprojet, Fr.

SOURCE: Fr. Demande, 32 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----

FR 2856596	A1	20041231	FR 2003-7836
20030627			
FR 2856596	B1	20070427	
CA 2530381	A1	20050106	CA 2004-2530381
20040625			
WO 2005000315	A1	20050106	WO 2004-FR1628
20040625			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1641461	A1	20060405	EP 2004-767475
20040625			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

JP 2007516160	T	20070621	JP 2006-516331
20040625			
MX 2005013877	A	20060313	MX 2005-13877
20051216			
US 20060210624	A1	20060921	US 2005-562396
20051227			

PRIORITY APPLN. INFO.: FR 2003-7836 A

20030627 WO 2004-FR1628 W

20040625

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:79960

IC ICM A61K031-4453

ICS A61K031-4164; A61P025-24; A61P025-18; A61K031-5513; A61K031-517; A61K031-554; A61K031-496

CC 63-6 (Pharmaceuticals)

IT 5786-21-0, Clozapine 85650-52-8, Mirtazapine 106266-06-2, Risperidone 111974-69-7 132539-06-1, Olanzapine

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as antipsychotic or antidepressant; new psychiatric drug
formulation
with an antipsychotic or antidepressant and an histamine H3
receptor
antagonist for prevention of psychotropic adverse effects)
IT 288-32-4D, Imidazole, derivative 362665-56-3,
3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(as histamine H3 receptor antagonist; new psychiatric drug
formulation
with an antipsychotic or antidepressant and an histamine H3
receptor
antagonist for prevention of psychotropic adverse effects)

L6 3128 S L4
L7 10 S L6 AND HISTAMINE H3 RECEPTORS/IT
L8 2 S L7 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2010 ACS on STN
TI New psychiatric drug formulation with an antipsychotic or
antidepressant
and an histamine H3 receptor antagonist for the prevention of
psychotropic
adverse effects

AB The invention relates to a drug formulation with an antipsychotic
or an antidepressant, which causes adverse effects like body
weight gain or sedation when administered, and an histamine H3
receptor antagonist or inverse agonist. The histamine H3 receptor
antagonist or inverse agonist should be present in the formulation
in therapeutically effective quantities to ensure at least one of
the three following effects on the adverse effects induced by the
antipsychotic or the antidepressant: suppression or limitation of
weight gain, suppression or limitation of the decrease in
vigilance, enhancement of the pro-cognitive effect of the
treatment.

ACCESSION NUMBER: 2005:589 HCAPLUS Full-text
DOCUMENT NUMBER: 142:79960
TITLE: New psychiatric drug formulation with an
antipsychotic
or antidepressant and an histamine H3 receptor
antagonist for the prevention of psychotropic
adverse
effects

INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte,
Jeanne Marie

PATENT ASSIGNEE(S): Bioprojet, Fr.
SOURCE: Fr. Demande, 32 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----

```

-----
      FR 2856596          A1      20041231      FR 2003-7836
20030627 <--
      FR 2856596          B1      20070427
      CA 2530381          A1      20050106      CA 2004-2530381
20040625 <--
      WO 2005000315       A1      20050106      WO 2004-FR1628
20040625 <--
      W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH,
      CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD,
      GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC,
      LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NI,
      NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SY,
      TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
      RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
      AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
      EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,
RO, SE,
      SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE,
      SN, TD, TG
      EP 1641461          A1      20060405      EP 2004-767475
20040625 <--
      R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
      IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
      JP 2007516160       T      20070621      JP 2006-516331
20040625 <--
      MX 2005013877       A      20060313      MX 2005-13877
20051216 <--
      US 20060210624       A1      20060921      US 2005-562396
20051227 <--
PRIORITY APPLN. INFO.:          FR 2003-7836          A
20030627 <--
                                WO 2004-FR1628          W
20040625
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):          MARPAT 142:79960
IC   ICM  A61K031-4453
      ICS  A61K031-4164; A61P025-24; A61P025-18; A61K031-5513; A61K031-
517;
      A61K031-554; A61K031-496
CC   63-6 (Pharmaceuticals)
IT   Histamine H3 receptors
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (new psychiatric drug formulation with an antipsychotic or
      antidepressant and an histamine H3 receptor antagonist for
prevention
      of psychotropic adverse effects)

```

IT 5786-21-0, Clozapine 85650-52-8, Mirtazapine 106266-06-2,
Risperidone
111974-69-7 132539-06-1, Olanzapine
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(as antipsychotic or antidepressant; new psychiatric drug
formulation
with an antipsychotic or antidepressant and an histamine H3
receptor
antagonist for prevention of psychotropic adverse effects)

L9 89 S L4 AND HISTAMINE
L10 15 S L9 AND (H3)
L11 4 S L10 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L12 3 S L11 NOT L5
L13 275 S L4 AND BODY WEIGHT/IT
L14 49 S L13 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L15 48 S L14 NOT L5
L16 1085 S HISTAMINE H3 RECEPTORS/IT
L17 33 S L16 AND BODY WEIGHT/IT
L18 15 S L17 AND (ANTIDEPRESSANT? OR ANTIPSYCHOTIC? OR
PSYCHOTROPIC? 0
L19 14 S L18 NOT L5
L20 11 S L17 AND ANTIDEPRESSANTS/IT
L21 10 S L20 NOT L5
L22 12 S L3 AND HISTAMINE H3 RECEPTORS/IT
L23 0 S L12 AND BODY WEIGHT/IT
L24 1 S L22 AND BODY WEIGHT/IT

L24 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN

TI New psychiatric drug formulation with an antipsychotic or
antidepressant
and an histamine H3 receptor antagonist for the prevention of
psychotropic
adverse effects

AB The invention relates to a drug formulation with an antipsychotic
or an antidepressant, which causes adverse effects like body
weight gain or sedation when administered, and an histamine H3
receptor antagonist or inverse agonist. The histamine H3 receptor
antagonist or inverse agonist should be present in the formulation
in therapeutically effective quantities to ensure at least one of
the three following effects on the adverse effects induced by the
antipsychotic or the antidepressant: suppression or limitation of
weight gain, suppression or limitation of the decrease in
vigilance, enhancement of the pro-cognitive effect of the
treatment.

ACCESSION NUMBER: 2005:589 HCAPLUS Full-text

DOCUMENT NUMBER: 142:79960

TITLE: New psychiatric drug formulation with an
antipsychotic

or antidepressant and an histamine H3 receptor
antagonist for the prevention of psychotropic

adverse

effects

INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte,

Jeanne Marie
 PATENT ASSIGNEE(S): Bioprojet, Fr.
 SOURCE: Fr. Demande, 32 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856596	A1	20041231	FR 2003-7836	
20030627				
FR 2856596	B1	20070427		
CA 2530381	A1	20050106	CA 2004-2530381	
20040625				
WO 2005000315	A1	20050106	WO 2004-FR1628	
20040625				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641461	A1	20060405	EP 2004-767475	
20040625				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007516160	T	20070621	JP 2006-516331	
20040625				
MX 2005013877	A	20060313	MX 2005-13877	
20051216				
US 20060210624	A1	20060921	US 2005-562396	
20051227				
PRIORITY APPLN. INFO.:			FR 2003-7836	A
20030627				
			WO 2004-FR1628	W
20040625				
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):			MARPAT 142:79960	

IC ICM A61K031-4453
 ICS A61K031-4164; A61P025-24; A61P025-18; A61K031-5513; A61K031-517;
 A61K031-554; A61K031-496
 CC 63-6 (Pharmaceuticals)
 IT Body weight
 (gain, as an adverse effect from antipsychotics and
 antidepressants;
 new psychiatric drug formulation with an antipsychotic or
 antidepressant and an histamine H3 receptor antagonist for
 prevention
 of psychotropic adverse effects)
 IT Histamine H3 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (new psychiatric drug formulation with an antipsychotic or
 antidepressant and an histamine H3 receptor antagonist for
 prevention
 of psychotropic adverse effects)
 IT 288-32-4D, Imidazole, derivative 362665-56-3,
 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (as histamine H3 receptor antagonist; new psychiatric drug
 formulation
 with an antipsychotic or antidepressant and an histamine H3
 receptor
 antagonist for prevention of psychotropic adverse effects)

L25 2 S L22 AND (ANTIDEPRESSANT? OR ANTIPSCYHOTIC?)
 L26 0 S L25 NOT L5
 L27 3 S L22 AND MENTAL AND BEHAVIORAL DISORDERS/IT
 L28 1 S L27 NOT L5

FILE 'REGISTRY' ENTERED AT 17:01:07 ON 25 MAR 2010
 E 362665-56-3/RN
 L29 1 S E15